Baird downgrades Genentech (NYSE: DNA) to Neutral based on valuation. Price target $95.

Baird analyst says, "With the stock trading ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE